Abstract 2047
Background
TSAs are common side effects among cancer pts undergoing chemotherapy and may lead to inadequate dietary intake and reduced quality of life. Here, we investigate the incidence of multiple components of self-reported TSAs and its etiological determinants in a homogeneous group of pts with stage II-III CC.
Methods
We used data collected in an ongoing observational study within the Prospective Dutch Colorectal Cancer Cohort, designed to study nutritional factors and oncological outcomes. Pts receive questionnaires on dietary intake by food-frequency questionnaire (past month average intake), dietary supplement use and TSAs at diagnosis (T0), and at 6, 12, 24 months post-diagnosis. Here, we selected pts with stage II-III CC, with completed T6 questionnaires and available clinical data.
Results
We included 87/468 pts for analysis (updated for ESMO) with a mean age 64.0±7.6 years, 70% male and 70% current/former smokers. Adjuvant chemotherapy (ACT), received by 52% of pts, consisted of CAPOX (90%), FOLFOX (5%), or CAP (5%) as initial regimen. TSAs were reported at T0 (4% of pts) and at T6 (32% of pts). TSA presence was significantly related to receiving ACT (RR 13.8, 95%CI: 3.5-54.3), but not to age, sex, education and smoking status. ACT treated pts more often reported a change in taste ability (49%, p < 0.001), change in taste perception (51%, p < 0.001), dry mouth (29%, p < 0.001), bad taste (38%, p < 0.001), and metallic taste (18%, p = 0.006), compared to pts who did not receive ACT. Pts with TSAs did not significantly differ from pts without TSAs in terms of caloric intake at T6 (p = 0.69). Caloric intake was low (no-TSA (n = 59) 1772 kCal and TSA (n = 28) 1809 kCal) and was below the ESPEN guidelines on nutrition in cancer patients for both groups.
Conclusions
TSAs are more prevalent in CC pts who received ACT compared to pts who did not, with taste more affected than smell. Pts had caloric intake below guideline recommendations at T6. The influence of TSAs on caloric intake appears to be limited when caloric intake is already insufficient. More pts, follow-up, and data on macronutrients and quality of life are needed to confirm and enrich these preliminary findings and ultimately help improve supportive care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Medical Center Utrecht.
Funding
Province of Utrecht, The Netherlands.
Disclosure
B. Dorresteijn: Full / Part-time employment: Danone Nutricia Research. M. Jourdan: Full / Part-time employment: Danone Nutricia Research. All other authors have declared no conflicts of interest.
Resources from the same session
5054 - Inhibition of Rspo-Wnt pathway Facilitates Checkpoint Blockade Therapy by anti-RSPO3 antibody (DBPR117)
Presenter: John Hsu
Session: Poster Display session 1
Resources:
Abstract
3305 - A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumors
Presenter: Jürgen Krauss
Session: Poster Display session 1
Resources:
Abstract
5353 - Phase 1/2 Study of 9-ING-41, a small molecule selective Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors
Presenter: Benedito Carneiro
Session: Poster Display session 1
Resources:
Abstract
3946 - Trial in progress: a Phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumors (NCT03447314).
Presenter: Aaron Hansen
Session: Poster Display session 1
Resources:
Abstract
3449 - Radiographic Phenotyping to Identify Intracranial Disseminated Recurrence in Brain metastases Treated With Radiosurgery Using Contrast-enhanced MR Imaging
Presenter: CheYu Hsu
Session: Poster Display session 1
Resources:
Abstract
4553 - Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer
Presenter: Lijuan Chen
Session: Poster Display session 1
Resources:
Abstract
4942 - Response assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: a comparison of RECIST 1.1, RANO and iRANO criteria
Presenter: Emilie Le Rhun
Session: Poster Display session 1
Resources:
Abstract
3529 - Management of multiple brain metastases by Staged SRS focusing on utmost risk lesions
Presenter: shaoqun Li
Session: Poster Display session 1
Resources:
Abstract
5315 - Whole brain radiotherapy plus simultaneous in-field boost versus whole brain radiotherapy plus fractionated stereotactic radiotherapy for multiple brain metastases of non-small cell lung cancer
Presenter: Lu Li
Session: Poster Display session 1
Resources:
Abstract
1116 - 3D based texture analysis serving as potential diagnostic factor in discriminating primary central nervous system lymphoma from metastatic brain tumors: A preliminary study
Presenter: Wen Guo
Session: Poster Display session 1
Resources:
Abstract